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ABSTRACT
Background. The evidence base regarding the safety of intrave-
nous (IV) iron therapy in patients with chronic kidney disease
(CKD) is incomplete and largely based on small studies of rela-
tively short duration.
Methods. FIND-CKD (ClinicalTrials.gov number
NCT00994318) was a 1-year, open-label, multicenter, prospec-
tive study of patients with nondialysis-dependent CKD, anemia
and iron deﬁciency randomized (1:1:2) to IV ferric carboxymal-
tose (FCM), targeting higher (400–600 mg/L) or lower (100–200
mg/L) ferritin, or oral iron. A post hoc analysis of adverse event
rates per 100 patient-years was performed to assess the safety of
FCM versus oral iron over an extended period.
Results. The safety population included 616 patients. The inci-
dence of one or more adverse events was 91.0, 100.0 and 105.0
per 100 patient-years in the high ferritin FCM, low ferritin FCM
and oral iron groups, respectively. The incidence of adverse
events with a suspected relation to study drug was 15.9, 17.8
and 36.7 per 100 patient-years in the three groups; for serious
adverse events, the incidence was 28.2, 27.9 and 24.3 per 100
patient-years. The incidence of cardiac disorders and infections
was similar between groups. At least one ferritin level 800 mg/
L occurred in 26.6% of high ferritin FCM patients, with no asso-
ciated increase in adverse events. No patient with ferritin 800
mg/L discontinued the study drug due to adverse events.
Estimated glomerular ﬁltration rate remained the stable in all
groups.
Conclusions. These results further support the conclusion that
correction of iron deﬁciency anemia with IV FCM is safe in
patients with nondialysis-dependent CKD.
Keywords: anemia, cardiovascular disease, oxidative stress
INTRODUCTION
It is estimated that iron deficiency affects over half of all adults
with chronic kidney disease (CKD) Stage 3 or 4 [1], with
adverse consequences for both erythropoiesis and nonhemato-
poietic cellular functions for which iron is essential [2]. The
Kidney Disease: Improving Global Outcomes (KDIGO)
Clinical Practice Guideline for Anemia in CKD suggests that
clinicians consider iron therapy in patients with a serum ferritin
concentration 500 mg/L, or a transferrin saturation (TSAT)
level 30%, if they desire an increase in hemoglobin (Hb) or
reduction of erythropoiesis-stimulating agent (ESA) dose [3].
Recent years have seen the introduction of new intravenous
(IV) iron preparations that permit administration of larger sin-
gle doses, expanding treatment opportunities [4]. However, if
weakly bound ‘labile’ iron is released rapidly from IV iron com-
plexes, the transport protein transferrin can become saturated.
This can lead to significant amounts of nontransferrin-bound
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|iron that can induce oxidative stress by catalyzing lipid peroxi-
dation and reactive oxygen species formation [5], potentially
contributing to endothelial injury with adverse cardiovascular
or renal consequences [6]. There are also concerns that follow-
ing IV iron therapy increased amounts of iron could become
available to invading microbes [7], which, coupled with
impaired immunological responses in the presence of excess
iron [6], could increase the risk for infection.
Further evidence is required concerning the relative safety of
different iron therapies in patients with CKD. However, trials of
IV iron therapy in patients with nondialysis-dependent CKD
have been relatively small and of short duration [8]. The evi-
dence base regarding safety is incomplete, as discussed recently
at a conference convened by the KDIGO initiative to identify
gaps in knowledge so as to inform future clinical research [9].
FIND-CKD (FerinjectVR assessment in patients with Iron
deficiency anemia and NonDialysis-dependent Chronic Kidney
Disease) was a randomized, multicenter trial of IV ferric car-
boxymaltose (FCM) versus oral iron in patients with
nondialysis-dependent CKD and iron deficiency anemia who
were not receiving treatment with an ESA [10]. The primary
objective of the study was to test whether FCM reduces the need
for alternative anemia therapy (e.g. blood transfusion or ESA
therapy) compared with oral iron in this setting. Safety data
were captured throughout the 1-year study. A post hoc analysis
of adverse event rates per 100 patient-years was performed to
assess the safety of FCM versus oral iron over an extended
period.
MATERIALS AND METHODS
FIND-CKD was a 56-week, open-label, multicenter, prospec-
tive, randomized, three-arm study undertaken at 193 nephrol-
ogy centers in 20 countries during 2009–12 (ClinicalTrials.gov
number NCT00994318) [10].
Study population
Eligibility criteria have been described in full previously [10].
Adult patients with nondialysis-dependent CKD were eligible if
(i) at least one Hb level was 9–11 g/dL; (ii) any ferritin level was
<100 mg/L, or<200 mg/L with TSAT<20%; (iii) estimated glo-
merular filtration rate (eGFR) was 60 mL/min/1.73 m2
[Modification of Diet in Renal Disease-4 (MDRD-4) equation
[11]] and eGFR loss was 12 mL/min/1.73 m2/year with pre-
dicted eGFR at 12 months 15 mL/min/1.73 m2; and (iv) no
ESA therapy was received within 4 months of randomization.
Exclusion criteria included a documented history of discontinu-
ing oral iron products due to significant gastrointestinal distress
and active malignancy.
Study treatment
Patients were randomized in 1:1:2 ratio to high ferritin FCM,
low ferritin FCM or oral iron. FCM dose (FerinjectVR , Vifor
International, St Gallen, Switzerland) in the high ferritin and
low ferritin FCM groups was adjusted to target a ferritin level of
400600 and 100–200 mg/L, respectively [10]. Oral iron therapy
consisted of commercially available ferrous sulfate at a dose of
304 mg (100 mg of iron) twice daily toWeek 52.
Until Week 8 post-randomization, patients were not to
receive ESAs, blood transfusion or any anemia therapy other
than study drug unless there was an absolute requirement.
Safety data collection
All adverse events and serious adverse events were recorded
at every study visit. A second or subsequent occurrence of the
same adverse event in the same patient was documented.
An adverse event was classified as serious if it resulted in
death, was life-threatening, required or prolonged hospitaliza-
tion, led to persistent or significant disability/incapacity or was
considered an important medical event. An event was classified
as ‘related’ to study drug if a causal relationship between the
event and the study drug was at least a reasonable possibility
based on the investigator’s medical judgement. In addition,
adverse events that required hospitalization are described
separately.
Ferritin and Hb were measured centrally. TSAT and C-reac-
tive protein were measured locally. eGFR was calculated based
on theMDRD-4 equation using locally measured creatinine val-
ues [11]. All laboratory values are reported for the intention-to-
treat population (n¼ 616).
Statistical analysis
Adverse events and serious adverse events are reported per
100 patient-years of follow-up, both as (i) incidence, i.e. occur-
rence of one or more event and (ii) the cumulative number of
events, i.e. every event regardless of whether it recurred in the
same patient. The latter approach ensures that multiple occur-
rences of the same event in the same patient are recognized.
Event rates were analyzed as only descriptive analyses, and no
statistical inference was performed. Performing multiplicity
testing and generating P-values for each category of adverse
events for a nonsafety study was not deemed appropriate and
would highly inflate global type-1 error.
Adverse events and serious adverse events are reported up to
the point at which another anemia therapy was initiated and/or
the randomized study medication was discontinued (‘the safety
period’). For neoplasms, all events during the total study period
to the final follow-up visit are reported. Additionally, the cumu-
lative number of adverse events, serious adverse events, serious
adverse events of special interest (events classified as cardiac
disorders or as infections) and hospitalizations due to adverse
events are reported during the total study period (i.e. to the final
follow-up visit).
Safety analyses were based on all patients who received at
least one dose of randomized treatment (the safety population).
All statistical analyses were performed at the 5% level using
SAS Version 9.3VR (SAS Institute Inc., SAS/STAT, Cary, NC,
USA). Continuous outcomes (e.g. ferritin levels) were analyzed
by ANCOVA. Binary outcomes such as onset of neoplasm were
analyzed by logistic regression methodology. Time to event out-
comes were analyzed by the log-rank statistic on Kaplan–Meier
survival curves.
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RESULTS
Patient population
In total, 626 patients were randomized. Of these, 10 did not
receive any study drug, such that the safety population included
616 patients (154 high ferritin FCM, 150 low ferritin FCM, 312
oral iron). The study was completed by 519 patients. The most
frequent reasons for study discontinuation were patient with-
drawal (n ¼ 53), death (n ¼ 20) and adverse events (n ¼ 13)
(Figure 1).
Demographic and baseline characteristics showed no
marked differences between the three treatment groups
(Table 1). The medical history was as expected for a population
of patients with CKD and was similar between groups.
Hypertension was present at the time of study entry in 31.2,
32.7 and 23.7% of patients in the high ferritin FCM, low ferritin
FCM and oral iron groups. A history of neoplasm was reported
in 20.1, 17.3 and 15.4% of patients, respectively.
Treatment
The mean [standard deviation (SD)] cumulative dose of
FCM of the safety population was 2685 (978) mg iron and 1040
(618) mg iron in the high ferritin and low ferritin groups,
respectively; the mean (SD) number of FCM injections was 4.2
(1.7) (range 1–10) and 5.2 (3.1) (range 1–14). The mean (SD)
cumulative dose of oral iron was 52 435 (24 768) mg iron, and
the mean (SD) total number of oral iron tablets was 524 (248)
(range 2–800).
Observation time
The mean (SD) observation time from first dose of study
drug to the end of the safety period was 10.8 (3.7) months in the
high ferritin FCM group [median (interquartile range, IQR)
13.0 months (9.2, 13.0)], 10.3 (4.1) months in the low ferritin
FCM group [median 12.8 months (7.4, 13.0)] and 9.4 (5.0)
months in the oral iron group [median 12.8 months (4.0, 13.0)].
The total number of patient-years of follow-up was 138.5, 129.0
and 242.8 in the high ferritin FCM, low ferritin FCM and oral
iron groups, respectively, and 267.8 years for both FCM groups
combined.
Iron status
In the high ferritin FCM group, mean (SD) ferritin level
increased from 58 (48) mg/L at baseline [median (IQR) 51 mg/L
(15, 81)] to 403 (190) mg/L at Week 4 [median (IQR) 401 mg/L
(255, 542)] and to 592 (195) mg/L at Week 24 [median (IQR)
583 mg/L (491, 670)], plateauing thereafter to Week 52, when
the mean level was 585 (171) mg/L [median (IQR) 547 mg/L
(476, 650)]. In the low ferritin FCM group, there was a gradual,
smaller increase in ferritin which plateaued from Week 36
onwards; mean (SD) ferritin at Week 52 was 139 (57) mg/L
[median (IQR) 132 mg/L (99, 169)]. Values in the oral iron
group increased gradually throughout the study, reaching 199
(135) mg/L at Week 52 [median (IQR) 181 mg/L (123, 432)].
Ferritin level was significantly higher in the high FCM group
versus the oral iron group fromWeek 4 onwards [all P< 0.001,
analysis of covariance (ANCOVA) analysis].
All groups showed an increase in TSAT byWeek 4. AtWeek
52, mean (SD) values for TSAT were higher in the high ferritin
FCM group [31.4 (10.5)%] [median (IQR) 29.0% (26.0, 36.0)]
and oral iron group [29.3 (16.5)%] [median (IQR) 26.0% (20.0,
33.0)] than in the low ferritin FCM group [23.8 (9.4)%] [median
(IQR) 23.0% (18.0, 28.0)], but within KDIGO guidelines for all
three groups [3].
FIGURE 1: Patient disposition (safety population). FCM, ferric carboxymaltose.
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Ferritin 800 mg/L occurred at least once in 41 patients
(26.6%) in the high ferritin FCM group, 9 of whom had at least
two consecutive measurements of ferritin 800 mg/L (5.8%).
Ferritin 800 mg/L was not observed in any patient in the low
ferritin FCM group, and in only one patient (0.3%) in the oral
iron group. In the high ferritin FCM group, ferritin1000 mg/L
occurred at least once in 13 patients (8.4%), and ferritin 1200
mg/L occurred at least once in 5 patients (3.2%). One patient
randomized to oral iron had ferritin 1000 mg/L (0.3%). The
mean total dose of FCM in the high ferritin group was similar in
patients with one or more ferritin values 800 mg/L, 2561 mg
iron compared with the overall high ferritin FCM group (2685
mg iron). The incidences of adverse events and serious adverse
events in patients with serum ferritin 800 mg/L (80.5 and
24.4%) were comparable to those seen in the overall safety pop-
ulation. No patient in the high ferritin FCM group with serum
ferritin 800 mg/L at any time discontinued the study drug due
to adverse events.
Low ferritin levels
The incidences of adverse events and serious adverse events
in patients randomized to low ferritin FCM and oral iron in
whom ferritin 200 mg/L was observed at least once were 88.1
and 23.1% for low ferritin FCM (n ¼ 143) and 80.6 and 16.9%
for oral iron (n ¼ 278). For patients in whom the ferritin level
was always 200 mg/L, the incidences of adverse and serious
adverse events were 90.1 and 25.7% in the low ferritin FCM
group (n ¼ 101), and 82.6 and 21.0% in the oral iron group
(n¼ 167).
FCM dose
Data from the high ferritin FCM and low ferritin FCM
groups were pooled to assess adverse events according to quar-
tiles of total FCM dose (<1000, 1000 to<1650, 1650–2500 and
>2500 mg iron). The mean duration of follow-up for safety
events was somewhat lower for patients in the lowest quartile of
FCM dose (265 days) compared with patients receiving 1000 to
<1650, 1650–2500 or >2500 mg iron (336, 337 and 346 days,
Table 1. Baseline characteristics and relevant medical history (safety population)
High ferritin FCM (n ¼ 154) Low ferritin FCM (n ¼ 150) Oral iron (n ¼ 312)
Age, years 69.5 (12.6) 68.1 (13.3) 69.3 (13.4)
Male gender, n (%) 62 (40.3) 54 (36.0) 116 (37.2)
White, n (%) 150 (97.4) 142 (94.7) 295 (94.6)
Body mass index, kg/m2 29.7 (6.6) 29.9 (6.0) 29.1 (5.9)
eGFR, mL/min/1.73 m2
Mean (SD) 32.9 (11.7) 31.5 (10.7) 32.2 (11.5)
Median (IQR) 32 (24, 40) 30 (23, 39) 31 (24, 38)
Hemoglobin, g/dL
Mean (SD) 10.3 (0.7) 10.5 (0.8) 10.4 (0.7)
Median (IQR) 10.3 (10.0, 10.7) 10.6 (10.1, 11.0) 10.5 (7.3, 12.1)
Ferritin, mg/L
Mean (SD) 58 (48) 55 (48) 57 (42)
Median (IQR) 50 (16, 81) 44 (17, 80) 50 (26, 80)
Transferrin saturation, %
Mean (SD) 16.2 (16.6) 16.1 (8.3) 15.5 (7.6)
Median (IQR) 14.2 (9.2, 19.2) 14.3 (10.0, 19.3) 15.0 (9.4, 20.0)
C-reactive protein, mg/L
Mean (SD) 6.8 (11.2) 6.2 (9.1) 5.2 (6.0)
Median (IQR) 3.5 (2.0, 7.6) 4.0 (1.7, 7.1) 3.5 (1.6, 6.3)
Medical history
Hypertension, n (%)
History of hypertension 134 (87.0) 133 (88.7) 268 (85.9)
Hypertension at study entrya 48 (31.2) 49 (32.7) 74 (23.7)
Cardiac disorder, n (%) 75 (48.7) 72 (48.0) 155 (49.7)
Atrial ﬁbrillation 22 (14.3) 20 (13.3) 31 (9.9)
Coronary artery disease 20 (13.0) 18 (12.0) 41 (13.1)
Myocardial ischemia 18 (11.7) 13 (8.7) 31 (9.9)
Myocardial infarction 13 (8.4) 11 (7.3) 22 (7.1)
Cardiac failure 8 (5.2) 13 (8.7) 30 (9.6)
Congestive heart failure 9 (5.8) 5 (3.3) 6 (1.9)
Acute myocardial infarction 5 (3.2) 5 (3.3) 1 (0.3)
Infection, n (%) 19 (18.8) 32 (21.3) 57 (18.3)
Urinary tract infection 9 (5.8) 4 (2.7) 15 (4.8)
Pneumonia 3 (1.9) 5 (3.3) 9 (2.9)
History of diabetes, n (%) 86 (57.1) 96 (64.0) 196 (62.8)
History of neoplasm, n (%) 31 (20.1) 26 (17.3) 48 (15.4)
Continuous variables are shown as mean (SD). The safety population included all patients who received one or more doses of randomized treatment.
FCM, ferric carboxymaltose; eGFR, estimated glomerular ﬁltration rate; IQR, interquartile range; SD, standard deviation.
aDeﬁned as systolic >145 mmHg or diastolic >95 mmHg.
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|respectively). From the lowest to the highest dose quartile, the
incidence of any adverse event was 79.5% (58/73), 87.3% (69/
79), 82.7% (67/81) and 85.9% (61/71); the cumulative number
of events per 100 patient-years was 393, 435, 477 and 417. For
serious adverse events, the incidence from the lowest to the
highest quartile of FCM dose was 17.8, 27.8, 25.9 and 26.8%,
with the cumulative number of events per 100 years being 36,
47, 41 and 40.
Adverse events
The incidence of one or more adverse events was 91.0, 100.0
and 105.0 per 100 patient-years in the high ferritin FCM, low
ferritin FCM and oral iron groups, respectively (Table 2). The
cumulative number of adverse events per 100 patient-years was
similar across treatment groups both during the safety period
(Table 3) and during the total study period to final follow-up
(Supplementary data, Table S1). The adverse events that
recurred (i.e. were reported more than once in the same patient)
most frequently were peripheral edema (1.8% of patients over-
all), diarrhea (1.6%), nasopharyngitis (1.1%), hypertension (1.1
%), urinary tract infection (1.0%) and hypoglycemia (1.0%).
The most common adverse events were gastrointestinal, the
incidence of which was 23.1, 29.5 and 52.7 per 100 patient-years
in the high ferritin FCM, low ferritin FCM and oral iron groups,
respectively (Table 2). The incidence of other frequently occur-
ring adverse events, including infections and cardiac disorders,
showed no clear differences between treatment groups
(Table 2).
The incidence of one or more adverse events with a sus-
pected relation to study drug was twice as high with oral iron
compared with FCM (15.9, 17.8 and 36.7 per 100 patient-years
in high ferritin FCM, low ferritin FCM and oral iron groups,
respectively), due to the higher incidence of gastrointestinal
events (Table 2). The cumulative number of adverse events with
a suspected relation to study drug per 100 patient-years was
31.0, 30.2 and 57.7, respectively.
The time to first adverse event, and particularly to first event
with a suspected relation to study drug, was shorter in the oral
iron group than in either FCM group (Table 2).
The incidence of one or more serious adverse events was
28.2, 27.9 and 24.3 per 100 patient-years in the high ferritin
FCM, low ferritin FCM and oral iron groups, respectively
(Table 2). The cumulative number of serious adverse events per
100 patient-years showed no marked difference between treat-
ment groups either during the safety period (Table 3) or during
the total study period to final follow-up (Supplementary data,
Table S1). The incidence of hospitalizations for adverse events,
and the cumulative number of such events, was also similar
between groups during the safety period (Table 4). The cumula-
tive number of hospitalizations for adverse events during the
total follow-up period was 42.5, 42.2 and 62.1 events per 100
patient-years in the high ferritin FCM, low ferritin FCM and
oral iron groups, respectively (Supplementary data, Table S2).
The first serious adverse event developed sooner in the oral iron
group (median 67 days post-baseline compared with 143 and
134 in the high ferritin and low ferritin FCM groups, respec-
tively). There were no serious adverse events with a suspected
relation to FCM.
Adverse events leading to study drug discontinuation were
rare under FCM [one and two in the high ferritin and low ferri-
tin groups, respectively, experienced one such event each (0.7
and 1.6 events per 100 patient-years)]. In the oral iron group, 22
patients (7.1%) experienced 26 adverse events which led to
study drug discontinuation (10.7 events per 100 patient-years),
at a median of 29 days after start of study drug. Discontinuation
of oral iron was overwhelmingly due to gastrointestinal adverse
events (20 out of 26 events).
Laboratory data
eGFR remained stable in all three groups during the study.
Mean (SD) values were 35.6 (13.8), 32.1 (12.7) and 33.4 (14.5)
mL/min/1.73 m2 in the high ferritin FCM, low ferritin FCM
and oral iron groups at Week 52, respectively, compared with
32.8 (11.7), 31.5 (10.7) and 32.3 (11.6) mL/min/1.73 m2 at
baseline.
Hypersensitivity reactions
Two treatment-related hypersensitivity reactions were
reported in the low ferritin FCM group. One was a nonserious
allergic reaction that occurred 29 days after the last of four
200 mg doses of FCM; administration of FCM was not
affected. The second event was a moderate allergic reaction in
which the patient developed fever and chills on the day of the
fourth FCM dose of 200 mg. FCM therapy was discontinued.
Both events resolved without treatment and there were no
sequelae. One patient in the oral iron group developed a rash,
which the investigator categorized as a serious adverse event
and considered to be a delayed hypersensitivity reaction
related to study drug; this led to oral iron discontinuation after
the first dose.
Infections
The incidence of one or more infections reported as
adverse events per 100 patient-years was similar in all three
treatment groups, both overall and for the most common
types of infection (Table 2). Infections reported as serious
adverse events were rare, occurring with an incidence of 4.3,
3.9 and 4.9 per 100 patient-years in the high ferritin FCM
group, low ferritin FCM group and oral iron group, respec-
tively. When assessed over the total study period to the final
follow-up visit, the cumulative number of serious adverse
events classified as infections was 5.1, 3.3 and 11.4 per 100
patient-years, respectively (Supplementary data, Table S1).
The incidence of hospitalizations due to infection was
similar between groups, but the cumulative number of such
events was numerically higher under oral iron (Table 4;
Supplementary data, Table S2).
Cardiovascular disorders
The incidence of one or more cardiac disorders was 15.2,
10.9 and 11.9 events per 100 patient-years in the high ferritin
FCM, low ferritin FCM and oral iron groups, respectively, dur-
ing the safety period (Table 2). Over the total study period to
final follow-up, the cumulative number of serious adverse
events classified as cardiac disorders was 9.7, 7.2 and 11.7 per
1534 S.D. Roger et al.
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Table 2. Incidences of one or more adverse event or serious adverse event per 100 patient-years (PY) during the safety perioda (safety population)
All events Events with suspected relation to study drug
High ferritin
FCM
(n ¼ 154)
(138.5 PY)
Low ferritin
FCM
(n ¼ 150)
(129.0 PY)
Oral iron
(n ¼ 312)
(242.8 PY)
High ferritin
FCM
(n ¼ 154)
(138.5 PY)
Low ferritin
FCM
(n ¼ 150)
(129.0 PY)
Oral iron
(n ¼ 312)
(242.8 PY)
Adverse events (per 100 PY) 91.0 100.0 105.0 15.9 17.8 36.7
No. patients with any adverse event (%) 126 (81.8) 129 (86.0) 255 (81.7) 22 (14.3) 23 (15.3) 89 (28.5)
Median time (days) to ﬁrst event 46 57 35 148 111 29
Gastrointestinal disorders (per 100 PY) 23.1 29.5 52.7 3.6 4.7 26.8
Diarrhea 10.8 8.5 18.5 1.4 – 7.8
Constipation 1.4 3.9 15.2 0.7 0.8 11.5
Nausea 6.5 5.4 6.2 0.7 1.6 2.9
Vomiting 4.3 3.1 5.4 – – 0.8
Dyspepsia 1.4 2.3 7.0 – 0.8 3.7
Infections (per 100 PY) 36.8 39.5 39.1 2.9 1.6 2.9
Urinary tract infection 13.0 7.8 7.0 0.7 – 0.4
Nasopharyngitis 9.4 7.8 6.6 0.7 – 0.4
Inﬂuenza 2.9 6.2 2.9 0.7 – 0.8
General disorders and administrative site conditions (per 100 PY) 26.0 27.1 27.6 2.9 2.3 1.2
Peripheral edema 15.2 16.3 11.9 0.7 – 0.8
Fatigue 0.7 4.7 5.8 – 1.6 –
Musculoskeletal and connective tissue disorders (per 100 PY) 25.3 32.6 23.1 3.6 2.3 2.9
Back pain 10.8 9.3 4.5 – 0.8 0.4
Arthralgia 7.2 5.4 6.2 – – 0.4
Pain in extremity 1.4 6.2 6.2 – 0.8 0.8
Muscle spasms 0.7 5.4 1.2 0.7 – –
Metabolism and nutrition disorders (per 100 PY) 22.4 24.8 25.5 – 0.8 2.9
Hypoglycemia 5.1 3.9 4.5 – – –
Hyperkalemia 3.6 5.4 2.9 – – –
Hyperglycemia 5.1 0 2.1 – – 0.4
Vascular disorders (per 100 PY) 23.8 20.2 21.4 2.9 1.6 0.8
Hypertension 15.2 10.9 13.2 2.2 0.8 0.4
Hypotension 5.8 3.1 2.1 0.7 – –
Respiratory, thoracic and mediastinal disorders (per 100 PY) 13.7 20.9 16.9 0.7 0.8 1.2
Dyspnea 5.1 8.5 4.5 – 0.8 0.4
Nervous system disorders (per 100 PY) 18.1 21.7 13.6 2.9 3.9 2.1
Dizziness 6.5 6.2 2.9 0.7 0.8 0.4
Headache 4.3 7.8 2.9 – 0.8 0.8
Investigations (per 100 PY) 15.9 15.5 17.7 2.9 – 2.1
Injury, poisoning and procedural complications (per 100 PY) 12.3 17.1 12.8 0.7 1.6 –
Cardiac disorders (per 100 PY) 15.2 10.9 11.9 1.4 0.8 –
Renal and urinary disorders (per 100 PY) 11.6 8.5 14.0 – 0.8 –
Skin and subcutaneous tissue disorders (per 100 PY) 11.6 9.3 13.2 – 0.8 –
Blood and lymphatic system disorders 5.8 8.5 5.4 0.7 1.6 –
Anemia (per 100 PY) 5.1 6.2 4.1 0.7 1.6 –
Neoplasms benign, malignant and unspeciﬁed (including cysts
and polyps)b (per 100 PY)
8.7 3.9 3.3 – 0.8 –
Serious adverse events (per 100 PY) 28.2 27.9 24.3 – – 0.4
No. of patients with any serious adverse event (%) 39 (25.3) 36 (24.0) 59 (18.9) 0 0 1 (0.3)
Median time (days) to ﬁrst event 143 134 67 – – 3
Cardiac disorders (per 100 PY) 7.2 5.4 5.8 – – –
Acute myocardial infarction 1.4 – 1.6
Cardiac failure 0.7 – 1.2
Cardiac failure congestive 1.4 0.8 0.4
Acute coronary syndrome 1.4 – 0.4
Infections (per 100 PY) 4.3 3.9 4.9 – – –
Pneumonia – 0.8 1.6
Renal and urinary disorders (per 100 PY) 4.3 1.6 5.4 – – –
Chronic renal failure 0.7 0.8 2.5
Musculoskeletal and connective tissue disorders (per 100 PY) 1.4 2.3 1.2 – – –
Back pain 1.4 0.8 –
Metabolism and nutrition disorders 2.9 4.7 2.9 – – –
Hypoglycemia (per 100 PY) 0.7 0.8 2.1
Diabetes mellitus – 2.3 0.4
Nervous system disorders (per 100 PY) 1.4 0.8 2.5 – – –
Syncope – – 1.2
The safety population included all patients who received one or more doses of randomized treatment.
aThe safety period included all events up to the point at which another anemia therapy was initiated and/or the randomized study medication was discontinued.
bAll events to ﬁnal follow-up are included.
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100 patient-years, respectively (Supplementary data, Table S1).
Hospitalization for adverse events classified as cardiac disorders
was similar in the three treatment groups (Table 4).
For major adverse cardiac events (MACE; acute myocardial
infarction, acute coronary syndrome, coronary artery disease,
unstable angina or myocardial ischemia) reported as serious
adverse events, the incidence was 3.6 in the high FCM group,
2.3 in the low FCM group and 3.3 events in the oral iron group
per 100 patient-years. There were no cases of stroke in any
treatment group.
Table 3. Cumulative number of adverse events and serious adverse events during the safety perioda (safety population)
High ferritin FCM (n ¼ 154)
(138.5 PY)
Low ferritin FCM (n ¼ 150)
(129.0 PY)
Oral iron (n ¼ 312)
(242.8 PY)
Adverse events
No. of patients 126 129 255
No. of events 607 553 1069
No. of events per 100 PY 438.3 428.7 440.3
Adverse events with suspected relation to study drug
No. of patients 22 23 89
No. of events 43 39 140
No. of events per 100 PY 31.0 30.2 57.7
Serious adverse events
No. of patients 39 36 59
No. of events 60 51 99
No. of events per 100 PY 43.3 39.5 40.8
Serious adverse events with suspected relation to study drug
No. of patients 0 0 1
No. of events 0 0 1
No. of events per 100 PY 0 0 0.4
Adverse events with suspected relation to study drug leading to study drug discontinuation
No. of patients (%) 1 (0.7) 2 (1.3) 23 (7.5)
No. of events 1 2 26
No. of events per 100 PY 0.7 1.6 10.7
Median time (days) to ﬁrst event 242 155 29
The safety population included all patients who received one or more doses dose of randomized treatment.
PY, patient-years.
aThe safety period included all events up to the point at which another anemia therapy was initiated and/or the randomized study medication was discontinued.
Table 4. (a) Incidence of one or more hospitalizations related to adverse events; (b) cumulative number of hospitalizations related to adverse events, during
the safety perioda (safety population)
High ferritin FCM (n ¼ 154)
(138.5 PY)
Low ferritin FCM (n ¼ 150)
(129.0 PY)
Oral iron (n ¼ 312)
(242.8 PY)
(a) Incidence of events
Hospitalization related to an adverse event
No. of patients (%) 33 (21.4) 35 (23.3) 57 (18.3)
No. of patients with events per 100 PY 23.8 27.1 23.5
Hospitalization related to an adverse event classiﬁed as a cardiac disorder
No. of patients (%) 7 (4.5) 6 (4.0) 13 (4.2)
No. of patients with events per 100 PY 5.1 4.7 5.4
Hospitalization related to an adverse event classiﬁed as an infection
No. of patients (%) 5 (3.2) 4 (2.7) 12 (3.8)
No. of patients with events per 100 PY 3.6 3.1 4.9
(b) Cumulative number of events
Hospitalization related to an adverse event
No. of events 50 48 95
No. of events per 100 PY 36.1 37.2 39.1
Hospitalization related to an adverse event classiﬁed as a cardiac disorder
No. of events 9 6 16
No. of events per 100 PY 6.5 4.7 6.6
Hospitalization related to an adverse event classiﬁed as an infection
No. of events 5 4 20
No. of events per 100 PY 3.6 3.1 8.2
The safety population included all patients who received one or more doses of randomized treatment.
PY, patient-years.
aThe safety period included all events up to the point at which another anemia therapy was initiated and/or the randomized study medication was discontinued.
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|Neoplasms
A total of 33 (5.4%) neoplasms, as defined by the study
investigator, were reported by the end of follow-up (mean
observation period 359 days), occurring in 13 patients (8.4%) in
the high ferritin FCM group, 7 patients (4.7%) in the low ferritin
FCM and 13 patients (4.2%) in the oral iron group. No obvious
pattern was seen for the type of neoplasms; the most frequent
neoplasm was basal cell carcinoma. One death, in the high FCM
group, was attributed to a neoplasm (recurrent laryngeal can-
cer). There were no statistically significant differences in the
incidence and time to first neoplasm between treatment groups.
Univariate and multivariate analyses showed that a previous
history of malignancy (which was highest in the high ferritin
group) was the only factor to exert a statistically significant (P<
0.05) impact on the development of neoplasms. None of the
neoplasms was thought to be related to a study treatment by
either the investigator or the Data Safety Monitoring Board.
Deaths
Twelve patients died during the safety period: five in the
high ferritin FCM group (cardiac arrest, myocardial infarction,
recurrent laryngeal cancer and respiratory failure), one in the
low ferritin FCM group (acute cardiac failure) and six in the
oral iron group (cardiac arrest, myocardial infarction, cerebro-
vascular accident, multiple myeloma, sepsis and multiple inju-
ries secondary to trauma). None of the deaths was considered to
be related to study drug by either the investigator or the Data
Safety Monitoring Board.
DISCUSSION
FIND-CKD studied the safety and efficacy of IV versus oral
iron in a randomized controlled trial of patients with
nondialysis-dependent CKD over a 1-year period and repre-
sents the most substantial data set for FCM in this setting.
While we previously reported the observed incidence in each
treatment arm [10], the current study extends the safety analysis
by reporting adverse event rates per 100 patient-years, thereby
accounting for differences in exposure, as well as event rates
according to applied FCM doses and iron status parameters,
and examines the occurrence of adverse events requiring hospi-
talization. Results showed that the incidence of serious adverse
events, and the incidence of events which required hospitaliza-
tion, was similar for both FCM regimens versus oral iron ther-
apy for the pre-specified safety period. No serious adverse event
was considered to be related to FCM administration. FCM tar-
geting either a higher or lower ferritin level showed half the inci-
dence of adverse events with a suspected relation to study drug
than oral iron, due to a lower incidence of gastrointestinal
symptoms. Ferritin levels of 800 mg/L or above in the high ferri-
tin FCM group were not associated with any increase in adverse
events or serious adverse events. Higher FCM doses also
showed no relation with increasing frequency of safety events.
Cardiac events, infections and renal function were of partic-
ular interest in light of concerns about a possible effect of IV
iron on oxidative stress levels and the risk of an effect on the
immune response. However, we found no differences. The inci-
dence and cumulative frequency of hospitalization due to either
cardiac disorders or infection was comparable between treat-
ment groups. In particular, we observed no evidence for an
increased risk of cardiac disorders or MACE with FCM com-
pared with oral iron, although even in this high-risk population
the number of patients could be insufficient to reveal a
difference.
No substantive difference in adverse events was observed
between the two FCM groups, despite an early profound rise in
serum ferritin levels in the high ferritin cohort, as per protocol,
which was sustained throughout the study. Elevated ferritin is
atypical in patients with CKD who are not on dialysis unless
they are acutely inflamed. Ferritin 800 mg/L occurred almost
exclusively in the high ferritin FCM group but was not associ-
ated with a higher rate of adverse events and did not lead to
study drug discontinuation. High ferritin concentrations were
generally transient, with few patients in the high ferritin FCM
group having more than one ferritin level of 800 mg/L (5.8%).
Only 8.4% had one or more than one ferritin level1000 mg/L.
Recent data from a single-center randomized study with 136
patients suggested a higher rate of cardiovascular events and
infections reported as serious adverse events during 2 years’
follow-up after an 8-week course of IV iron sucrose compared
with oral iron [12]. In that study, which was discontinued before
completion, there were 54.4 and 34.4 serious cardiovascular
events per 100 patient-years in the IV and oral iron treatment
groups. These findings are not consistent with FIND-CKD and
other recent randomized trials in patients with nondialysis-
dependent CKD [13, 14]. Notably, safety analyses from
REVOKE were reported as multiple events (whereby every
event is counted separately when a patient experiences repeated
events) instead of the more standard way of reporting adverse
events (whereby patients with repeated events are counted only
once), and repeated events in the same patient were largely
responsible for the observed difference. Despite using both
approaches in the present analysis, we observed no difference in
clinical adverse events between groups.
Although FIND-CKD was longer than previous completed
trials and included a relatively large study population, the analy-
sis had restricted power to detect small differences in the inci-
dence of adverse events between treatment groups that could
still be clinically meaningful. Moreover, follow-up time may still
have been too short to detect long-term effects. Follow-up time
differed between the three groups, being shorter in the oral iron
group, but safety events were analyzed per 100 patient-years to
account for this. Additionally, it should be borne in mind that
safety reporting was censored at the point at which another ane-
mia therapy (e.g. ESA or blood transfusion) was initiated and/
or the patient discontinued study drug. This approach was
taken in an attempt to obtain ‘clean’ data sets, but this advant-
age is counterbalanced by the risk that adverse events which
first manifested after drug discontinuation would not be cap-
tured, and is thus a potential source of under-reporting.
Inclusion of malignancies observed during the total follow-up
period, and analyses for other key safety parameters over the
same period, mitigates this limitation. Lastly, FIND-CKD also
has the limitation of not including a placebo arm, so that no
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|conclusions can be drawn on the effect of any iron therapy ver-
sus none.
In summary, these results further support the conclusion
that correction of iron deficiency anemia with IV FCM is safe in
patients with nondialysis-dependent CKD, consistent with
results from a recent meta-analysis of FCM across multiple
indications [15]. While this is encouraging, longer follow-up in
larger populations is required to definitively ascertain the long-
term safety profile of FCM and other IV iron therapies.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxfordjour
nals.org.
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